TSS
VTGN icon

Two Sigma Securities’s VistaGen Therapeutics VTGN Stock Holding History

Two Sigma Securities’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,495
Closed -$9.43K – 2431
2026
Q1 		$9.43K Buy
+16,495
New +$10K ﹤0.01% 1471
2023
Q2 		– Sell
-1,165
Closed -$4.36K – 3404
2023
Q1 		$4.36K Sell
1,165
-398
-25% -$2.09K ﹤0.01% 2536
2022
Q4 		$4.83K Sell
1,563
-374
-19% -$1.41K ﹤0.01% 2455
2022
Q3 		$9K Buy
+1,937
New +$19.2K ﹤0.01% 2420
2021
Q2 		– Sell
-430
Closed -$27K – 1740
2021
Q1 		$27K Buy
+430
New +$28.7K ﹤0.01% 766
2020
Q1 		– Sell
-2,441
Closed -$51K – 2382
2019
Q4 		$51K Buy
+2,441
New +$61.7K ﹤0.01% 2235

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Two Sigma Securities's VTGN Position: Q2 2026 in Review

Two Sigma Securities sold out of VistaGen Therapeutics (VTGN) in Q2 2026, closing a stake of 16,495 shares — an estimated $9.43K sold.

Two Sigma Securities first reported a position in VTGN in Q4 2019 and held it in 6 quarters. The position peaked at $51K in Q4 2019. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Two Sigma Securities reported no remaining VistaGen Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Two Sigma Securities sold 16,495 VistaGen Therapeutics shares in Q2 2026, an estimated $9.43K.
  • Two Sigma Securities first reported a position in VistaGen Therapeutics in Q4 2019 and held it in 6 quarters.
  • Two Sigma Securities's VistaGen Therapeutics position peaked at $51K in Q4 2019.
  • 49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.